Xenetic Biosciences, Inc.
XBIOXenetic Biosciences, Inc. (XBIO) is a biotechnology company focused on developing innovative biologic and immuno-oncology therapies. The company's portfolio includes proprietary platforms for novel cancer treatments, aiming to harness the immune system to fight cancer and other diseases. Xenetic collaborates with partners to advance its pipeline, emphasizing scalable biologic manufacturing and translational research.
Company News
Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 1.27% and 21.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 38.94% and 47.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 11.76% and 49.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Xenetic Biosciences (XBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
HC Wainwright has downgraded Xenetic Biosciences Inc (NASDAQ: XBIO) from Buy to Neutral, citing pending clinical path visibility. In the Q1 earnings release, the company announced continued progress with the DNase-based oncology program toward Phase 1 study for pancreatic carcinoma and other locally advanced or metastatic solid tumors. Xeneti...
